Chenotherapy for gallstone dissolution. I. Efficacy and safety.
Clinical experience with chenodeoxycholic acid therapy for dissolving gallstones is reported, with particular attention to determinants of response. Of 12 patients receiving 15 mg/kg/day or more, ten responded (83%); only 15 of 40 patients (38%) receiving less than 15 mg/kg/day responded. Large solitary stones and stones in gallbladders that visualized poorly after oral cholecystography had a lower response rate. Radiopaque stones did not respond in 18 patients. Five of ten patients with stones in the common bile duct responded. Small, dose-related elevations in SGOT were the only biochemical abnormality observed. Liver biopsy specimens showed no notable abnormality. Diarrhea was an infrequent problem. Stones recurred in three of 15 patients during six to 48 months of observation without treatment. Chenodeoxycholic acid, when given in adequate dosage, continues to appear promising as medical therapy for asymptomatic radiolucent gallstones in radiologically visualizing gallbladders.
D002635:Chenodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D002769:Cholelithiasis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D002986:Clinical Trials as Topic; D042882:Gallstones / Q000188:drug therapy; D006801:Humans; D011859:Radiography; D012008:Recurrence; D012995:Solubility
D002635:Chenodeoxycholic Acid